Conference Day Two
Wednesday, June 12

Day 2

8:00 am Registration & Coffee Room Networking

8:50 am Opening Remarks

9:00 am Full Landscape Overview of the Allogeneic Cell Therapy Space

9:30 am Unleashing the Potential of CAR-T in Earlier Lines of Cancer Treatment & Beyond

  • Zachary Roberts Executive Vice President, R&D, Chief Medical Officer, Allogene Therapeutics

10:00 am Morning Refreshment Break & Networking Break


As the allogeneic community is reunited, this session will ensure you can reconnect with your peers in the room to make new and lasting connections. Also, don’t forget to enjoy some refreshments before we split off into the 3 different tracks: Pre-Clinical, Clinical and Manufacturing & Process Development


Enhancing the Targeting & Infiltration of Solid Tumors

11:00 am Identifying Novel Cancer Biomarkers that Indicate Responsiveness to Allogeneic Cell Therapies

11:30 am Investigating Strategies for Trafficking & Infiltration of Allogeneic Cells into Solid Tumors

  • Rosa Ng Associate Director, Cell Therapy Innovation Lead Discovery, Takeda New!


Innovating in Allogeneic Clinical Trials to Bring Benefit to Patients Faster

11:00 am Optimizing Clinical Trials Using Global Patient Populations to Make Off-the-Shelf Therapies Truly Accessible

11:30 am Protecting Patients by Removing Need for Lymphodepletion to Better Preserve Immune Function

  • Paul Song Chief Executive Officer, NKGen Biotech New!


Advancements in Delivery & Storage of Allogeneic Cell Therapy Products

11:00 am Making the Ideal CDMO Match for Allogeneic Cell Therapy

  • Lan Le Senior Director, Aurion Biotech

11:30 am Panel: Are CDMO ready for phase appropriate manufacturing to move customer’s cell therapy programs ahead?

12:00 pm Lunch Refreshment

Mitigating Safety Risks & Challenges for Allogeneic Products

1:00 pm Leveraging the Unique Characteristics of NK Cells to Overcome Current Safety Concerns

  • Wei LI CSO, Cytovia Therapeutics New!

1:30 pm Defining Tolerable Safety Profiles for Novel Applications of Allogeneic Therapies

2:00 pm Leveraging Gamma Delta Cells to Enhance Accessibility of Allogeneic Therapies

  • Jeff Liter Chief Executive Officer, Luminary Therapeutics

Preparing Allogeneic Cells Against Immunosurveillance

1:00 pm Novel Ways to Improve an Allogeneic Invariant NKT cell Immunotherapy

1:30 pm Highlighting Cell Armoring Strategies to Protect Allogeneic Products During Delivery

  • Jeffrey Miller Professor of Medicine, Division of Hematology, Oncology and Transplantation Deputy Director, Masonic Cancer Center, Masonic Cancer Center New!

2:00 pm Overcoming Immunogenicity Using Novel Gene Edits

  • Evren Alici Co-Director - Next Generation NK Cell Competence Center & Research Group Leader, Karolinska Institutet

Implementing Effective Allogeneic Cell Therapy QC & Characterization

1:00 pm Characterizing Starting Material for Safety & Efficacy

1:30 pm Designing Screening Protocols to Build a Scalable Diverse Donor Pool for Off-the-Shelf Product Manufacturers

  • Mamta Kalra Sr Director Process and Analytical Development, Immatics GmbH

2:00 pm Breakthroughs in iPSC cell therapy and guide RNA

  • Xiulian Sun Founder & Chief Technical Officer, uBriGene

2:10 pm Assessment of Immunogenicity associated with Allogeneic CAR-T Cell Therapy

  • Lalit Kumar Director - Clinical Bioanalytics & Translational Science, Beam Therapeutics New!

2:30 pm Afternoon Break & Refreshments

Combining Next-Gen Platforms & Refreshed Business Strategies to Drive Investment into Allogeneic Cell Therapies

3:30 pm Leveraging a Novel Non-Gene Edited Platform to Enhance the Persistence & Efficacy of Allogeneic Cell Therapies

  • Eytan Breman Director - Research & Development, Celyad New!

4:00 pm Panel: Meet the Investors – Your Questions Answered

4:30 pm Closing Remarks & End of Conference